Format

Send to

Choose Destination
Clin Nucl Med. 2015 Sep;40(9):e448-50. doi: 10.1097/RLU.0000000000000862.

Reversal of Severe and Refractory Humoral Hypercalcemia With 177Lu-Octreotate Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumor of the Pancreas.

Author information

1
From the *Division of Nephrology, CHU de Québec, L'Hôtel-Dieu de Québec Hospital and Research Center, Faculty and Department of Medicine, Laval University, Quebec, Canada; †Department of Medical Imaging, CHU de Québec, and Department of Radiology, Laval University, Quebec City, Canada; ‡Division of Hematology-Oncology, CHU de Québec, L'Hôtel-Dieu de Québec Hospital, Faculty of Medicine, Laval University, Quebec, Canada; and §Department of Biochemistry, CHU de Québec, L'Hôtel-Dieu de Québec Hospital, Faculty of Medicine, Laval University, Quebec, Canada.

Abstract

A 48-year-old Caucasian male patient with newly diagnosed neuroendocrine tumor of the pancreas with multiple liver metastases developed severe and refractory hypercalcemia. Complementary investigations were compatible with humoral hypercalcemia with high parathyroid hormone-related peptide (PTHrP) levels. Hypercalcemia was refractory to medical treatments for more than 2 years. Serum calcium returned to normal values only after 4 cycles of peptide receptor radionuclide therapy with Lu-octreotate, with concomitant reduction of PTHrP level and tumor regression. The use of radionuclide therapy could be an option for the management of severe humoral hypercalcemia in patients with inoperable metastatic pancreatic neuroendocrine tumor.

PMID:
26053724
DOI:
10.1097/RLU.0000000000000862
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center